Change - Announcement of Appointment::Appointment of Executive Director, Chairman of the Board and Group CEO - Dr Bernard Ng Kee Huat

Issuer & Securities

Issuer/ Manager
META HEALTH LIMITED
Securities
META HEALTH LIMITED - SG1O81915033 - 5DX
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Appointment
Date &Time of Broadcast
06-Jun-2022 18:25:11
Status
New
Announcement Sub Title
Appointment of Executive Director, Chairman of the Board and Group CEO - Dr Bernard Ng Kee Huat
Announcement Reference
SG220606OTHRBRM5
Submitted By (Co./ Ind. Name)
Lee Wei Hsiung
Designation
Company Secretary
Description (Please provide a detailed description of the event in the box below)
Appointment of Dr Bernard Ng Kee Huat as an Executive Director of the Company, Chairman of the Board and Group Chief Executive Officer.

This announcement has been prepared by Meta Health Limited (the "Company") and its contents have been reviewed by the Company's sponsor, ZICO Capital Pte. Ltd. (the "Sponsor"), in accordance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited ("SGX-ST") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Alex Tan, Chief Executive Officer, ZICO Capital Pte. Ltd. at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, telephone (65) 6636 4201.

Additional Details

Date Of Appointment
07/06/2022
Name Of Person
Bernard Ng Kee Huat
Age
49
Country Of Principal Residence
Singapore
The Board's comments on this appointment (including rationale, selection criteria, board diversity considerations, and the search and nomination process)
The Nominating Committee of the Company ("NC") has reviewed the professional qualifications and working experience of Dr Bernard Ng Kee Huat ("Dr Bernard Ng") and recommended his appointment as an Executive Director of the Company, Chairman of the Board of Directors of the Company ("Board") and Group Chief Executive Officer, as part of the Company's strategic restructuring of its management team as it endeavors to diversify and expand into the digital healthcare industry. During the nomination process, the NC has also considered Dr Bernard Ng's performance as Executive Director of 5Digital Pte. Ltd. (a wholly-owned subsidiary of the Company).

The Board, having considered the NC's recommendation, approved the appointment of Dr Bernard Ng as an Executive Director of the Company, Chairman of the Board and Group Chief Executive Officer.
Whether appointment is executive, and if so, the area of responsibility
Executive. Responsible for overseeing the overall business strategy of the Group and the conduct of the Group's daily operational directions and decisions.
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Executive Director of the Company, Chairman of the Board and Group Chief Executive Officer
Professional qualifications
Doctor of Medicine
Master of Business Administration
Member of Singapore Institute of Directors
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/ or substantial shareholder of the listed issuer or any of its principal subsidiaries
Nil
Conflict of interests (including any competing business)
Nil
Working experience and occupation(s) during the past 10 years
Abbott Laboratories Asia, Australia, Africa, Middle East; July 2010 till February 2012

Sanofi Consumer Health, Business Development & Generics Division; March 2012 till January 2014

RB Global team in London; February 2014 till May 2017

Bayer Healthcare and Consumer Healthcare; August 2017 till December 2021

5Digital Pte. Ltd.; Since 7 January 2022
Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6))
Yes
Shareholding interest in the listed issuer and its subsidiaries?
No
# These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8).
Past (for the last 5 years)
Nil
Present
5Digital Pte. Ltd.
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?
No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?
No
(c) Whether there is any unsatisfied judgment against him?
No
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?
No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?
No
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?
No
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?
No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?
No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?
No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or
No
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or
No
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or
No
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?
No
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?
No
Any prior experience as a director of an issuer listed on the Exchange?
No
If no, please state if the director has attended or will be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange
Dr Bernard Ng completed 8 modules on Listed Entity Directors course by Singapore Institute of Directors on 22 October 2021.